Diseases & Conditions
Grants & Contracts
News & Events
January 10, 2023
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
December 08, 2022
As scientists learn more about SARS-CoV-2 and its infection tactics, nasal vaccines appear to be a promising response.
December 06, 2022
Developing a vaccine capable of fighting a diverse group of coronaviruses and viral variants remains a priority for NIAID, which NIAID has awarded an additional $26.1 million for four additional “pan-coronavirus” vaccine grant awards,
August 22, 2022
The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology
August 17, 2022
An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.
June 10, 2022
A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice.
June 07, 2022
NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.
May 19, 2022
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
May 18, 2022
Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development.
February 18, 2022
In an HIV.gov video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.
May 18, 2021
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
April 01, 2021
Single-dose experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected lungs and nasal regions from SARS-CoV-2 infection.
June 12, 2020
A vaccine developed to protect broadly against Mosquito-borne diseases appears safe in Phase 1 of a NIAID trial.
May 17, 2020
A safe and effective HIV vaccine remains elusive. On HIV Vaccine Awareness Day 2020, NIAID honors researchers and clinical study participants.
April 17, 2020
A NIAID-led trial has proven an experimental chikungunya vaccine to be both safe and to confer durable immune responses in healthy volunteers.
April 03, 2020
A candidate vaccine delivered though a thumbnail-sized patch studded with microneedles could help address the coronavirus disease 2019 (COVID-19) pandemic.
March 24, 2020
NIAID reiterates commitment to researching tuberculosis, the world’s leading cause of death from a single infectious disease.
March 16, 2020
An efficacy trial of an experimental vaccine to protect against many flu virus strains has yielded promising results.
February 24, 2020
Identifying predictors of autoimmune disease flare-ups could aid treatment for these conditions by allowing doctors to intervene before symptoms worsen. Recognizing immune system attributes that forecast a healthy person’s response to vaccination or infection would help researchers develop new vaccines. A new NIAID study connects these seemingly distinct avenues of research.